GlaxoSmithKline: Lymphoma, Non-Hodgkin trials
The registry lists 38 Lymphoma, Non-Hodgkin studies with GlaxoSmithKline as lead sponsor. 1 are open to participants now and 21 have results posted.
Phase 1 12Phase 2 22Phase 3 3No phase 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHLRecruitingNCT07607925Phase 1/2
- A Phase 1/2 Trial of SRA737 in Subjects With Advanced CancerCompletedNCT02797964Phase 1/2Results posted
- An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's LymphomaCompletedNCT02783300Phase 1Results posted
- PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)TerminatedNCT02378038Phase 2Results posted
- PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)CompletedNCT02226965Phase 2Results posted
- A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple MyelomaTerminatedNCT02082977Phase 1Results posted
- Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOPCompletedNCT01868035Phase 2Results posted
- Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT01733238Phase 2Results posted
- Open Label Multicenter Study of CVP Followed by Iodine-131 Anti-B1 Antibody for Subjects With Untreated Low-Grade Non Hodgkin's Lymphoma.CompletedNCT01663714Phase 2Results posted
- A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL)CompletedNCT01573000Phase 2Results posted
- Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas and Extended Study to Determine the Safety and Efficacy of Coulter Clone® 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's LymphomaCompletedNCT01536561Phase 1Results posted
- Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade HistologiesCompletedNCT01224821Phase 2Results posted
- Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's LymphomaCompletedNCT00996996Phase 2Results posted
- Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received RituximabCompletedNCT00996593Phase 2Results posted
- Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's LymphomaCompletedNCT00989664Phase 2Results posted
- Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive HistologyCompletedNCT00950755Phase 2Results posted
- Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 AntibodyCompletedNCT00938041Phase 2Results posted
- Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 TositumomabCompletedNCT00933335Phase 2Results posted
- Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)CompletedNCT00823719Phase 2Results posted
- A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's LymphomaCompletedNCT00315731Phase 1Results posted
- Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins LymphomaCompletedNCT00268983Phase 3Results posted
- Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's LymphomaCompletedNCT00268203Phase 2Results posted
- Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow InvolvementCompletedNCT00992758Phase 1
- Study to Assess the Pharmacokinetics and Pharmacodynamics of GSK461364 in Subjects With Non-Hodgkins LymphomaCompletedNCT00536835Phase 1
- A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18CompletedNCT00500058Phase 1
- A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic RegimenWithdrawnNCT00319332Phase 3
- Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Tositumomab and/or Iodine I 131 TositumomabCompletedNCT00240591
- Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Iodine I 131 TositumomabCompletedNCT00240578
- Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's LymphomaCompletedNCT00240565Phase 2
- Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)CompletedNCT00094848Phase 2
- Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular LymphomaWithdrawnNCT00092274Phase 1/2
- A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's LymphomaStatus unknownNCT00078598Phase 3
- Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 TositumomabCompletedNCT00062894Phase 1/2
- Expanded Access Study of Iodine-131 Anti-B1 AntibodyStatus unknownNCT00022958Not applicable
- Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOPStatus unknownNCT00022932Phase 2
- Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow InvolvementStatus unknownNCT00022906Phase 1
- Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's LymphomaStatus unknownNCT00022893Not applicable
- A Study of Azidothymidine (AZT) in the Treatment of HIV Infection in Patients Receiving a Bone Marrow TransplantCompletedNCT00002284Not applicable